



Comprehensive Review on Upper Tract Urothelial Carcinoma: An Update in 2023

Guest Editors:

Dr. Hooman Djaladat

Institute of Urology, Norris
Comprehensive Cancer Center,
University of Southern California,
Los Angeles, CA, USA

Dr. Alireza Ghoreifi

Institute of Urology, Norris
Comprehensive Cancer Center,
University of Southern California,
Los Angeles, CA, USA

Deadline for manuscript
submissions:

closed (31 December 2023)

Message from the Guest Editors

Upper tract urothelial carcinoma (UTUC) is a relatively uncommon type of cancer, yet its incidence has risen in the past few decades mainly due to improved detection through advanced imaging and endoscopic technologies. It is an aggressive tumor with up to 60% and 25% of patients presenting with non-organ confined and metastatic diseases at diagnosis, respectively. Moreover, despite surgery with curative intent, long-term cancer-specific survival is still low, predominantly due to undetected microscopic metastasis. The management and prognosis of UTUC have improved in recent years given the widespread use of minimally invasive approaches and novel neoadjuvant and adjuvant systemic therapies.

This Special Issue aims to highlight different aspects of multidisciplinary management of UTUC, including imaging, novel diagnostic markers, neoadjuvant and adjuvant therapies, and surgical interventions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)